3820 Does the frailty index applied to randomised controlled trials really measure frailty?
3820 Mischt der Frailty Index in randomisierten kontrollierten Studien Frailty wirklich?
Age and Ageing · 05.02.2026 · 55 (Supplement_1)
DOI: 10.1093/ageing/afaf368.116 ↗Auf einen Blick
Eine Analyse von 19 RCTs und 18 Beobachtungsstudien zeigte ähnliche Zahlen von Defiziten in Frailty Indices. In kardiovaskulären RCTs dominierten jedoch kardiometabolische Defizite.
Fragestellung
Erfassen Frailty Indices aus RCTs die Frailty inhaltlich ähnlich wie Frailty Indices aus Beobachtungsstudien?
Methode
Analyse von 19 RCTs und 18 Beobachtungsstudien aus aktuellen systematischen Übersichten; Vergleich von Anzahl, Datenquellen und physiologischer Domäne der Defizite.
Ergebnisse
RCT-FI: median 41 Defizite (IQR 35–50); Beobachtungsstudien: median 35 (IQR 31–45). In kardiovaskulären RCTs waren 47 % (IQR 38 %–51 %) der Defizite kardiometabolisch vs. 19 % (14 %–24 %) in Beobachtungsstudien.
Schlussfolgerung der Autor:innen
In vielen kardiovaskulären RCTs fokussieren FIs eher auf kardiometabolische Defizite als auf Funktionsmaße. Die Autor:innen betonen, dass solche Indizes die breite physiologische Vulnerabilität von Frailty nicht sicher abbilden.
Kernaussagen
- Ähnliche Defizitzahl in RCT- und Beobachtungs-FIs
- Kardiovaskuläre RCTs: mehr kardiometabolische Defizite
- Die Abbildung von Frailty in RCT-FIs bleibt fraglich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 05.02.2026. Verfasst von R Bousetta und 4 weiteren Autor:innen.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Cumulative deficit frailty indices (FI) from randomised controlled trials (RCT) are increasingly used to assess whether trial findings are applicable to people living with frailty. However, some applications of the frailty index have been criticised for including to narrow a range of deficits. The aim of this analysis is to examine the range and type of deficits included in these frailty indices and compared these to those from observational studies.
Methods
We identified 19 RCTs assessing treatment effect modification using the FI, as well as 18 observational studies assessing mortality risk associated with frailty, from recent systematic reviews. We extracted the FI deficits included from each study. We compared the number of deficits, data sources (e.g. medical history, physical measurements, questionnaires) and physiological domain (e.g. cardiometabolic, neuro-cognitive, physical function) of the deficits from each source.
Results
The number of deficits was similar between RCT frailty indices (median 41 deficits, interquartile range [IQR] 35–50) and observational studies (median 35, interquartile range 31–45). Broadly similar data sources were used to identify deficits. However, in RCTs of cardiovascular conditions, cardiometabolic deficits made up a greater proportion of deficits (median 47% of included deficits, IQR 38%–51%, compared to 19%, 14%–24%, in observational studies). Cardiovascular RCTs included fewer physical function measures (median 4% [3%–9%], compared to 16% in other RCTs of other conditions [13%–17%], 17% in observational [13%–23%]).
Conclusion
In many cardiovascular RCTs, FIs focus on cardiometabolic deficits rather than measures of function. It cannot be assumed that these FIs adequately capture the broad physiological vulnerability that characterises frailty in clinical practice. We need to establish if such indices adequately capture risk of outcomes of importance to people living with frailty if such studies are to inform care. Until then, caution is required when assessing applicability of trials to people living with frailty.
Zitieren
APA
Bousetta, R., McAllister, D. A., Wightman, H., Lewsey, J., & Hanlon, P. (2026). 3820 Does the frailty index applied to randomised controlled trials really measure frailty?. Age and Ageing, 55(Supplement_1). https://doi.org/10.1093/ageing/afaf368.116
Vancouver
Bousetta R, McAllister DA, Wightman H, Lewsey J, Hanlon P. 3820 Does the frailty index applied to randomised controlled trials really measure frailty?. Age and Ageing. 2026;55(Supplement_1). doi:10.1093/ageing/afaf368.116
BibTeX
@article{Bousetta2026,
author = {Bousetta, R and McAllister, D A and Wightman, H and Lewsey, J and Hanlon, P},
title = {3820 Does the frailty index applied to randomised controlled trials really measure frailty?},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {Supplement_1},
doi = {10.1093/ageing/afaf368.116}
}
EUVIMED